MTXPK.org: A Clinical Decision Support Tool Evaluating High-Dose Methotrexate Pharmacokinetics to Inform Post-Infusion Care and Use of Glucarpidase.
Taylor, ZL; Mizuno, T; Punt, NC; Baskaran, B; Sainz, AN; Shuman, W; Felicelli, N; Vinks, AA; Heldrup, J; Ramsey, LB.
Clinical Pharmacology and Therapeutics.
2020;
108:635-643.
Gene-based dose optimization in children.
Ramsey, LB; Brown, JT; Vear, SI; Bishop, JR; Van Driest, SL.
Annual Review of Pharmacology and Toxicology.
2020;
60:311-331.
Pharmacogenetics of treating pediatric anxiety and depression.
Ramsey, LB; Bishop, JR; Strawn, JR.
Pharmacogenomics.
2019;
20:867-870.
CYP2C19-Guided Escitalopram and Sertraline Dosing in Pediatric Patients: A Pharmacokinetic Modeling Study.
Strawn, JR; Poweleit, EA; Ramsey, LB.
Journal of Child and Adolescent Psychopharmacology.
2019;
29:340-347.
Pharmacogenetics of Sertraline Tolerability and Response in Pediatric Anxiety and Depressive Disorders.
Poweleit, EA; Aldrich, SL; Martin, LJ; Hahn, D; Strawn, JR; Ramsey, LB.
Journal of Child and Adolescent Psychopharmacology.
2019;
29:348-361.
Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving dasatinib.
Ramsey, LB; Mizuno, T; Vinks, AA; O'Brien, MM.
Pediatric Blood and Cancer.
2019;
66:e27618-e27618.
Association of SLCO1B1 *14 Allele with Poor Response to Methotrexate in Juvenile Idiopathic Arthritis Patients.
Ramsey, LB; Moncrieffe, H; Smith, CN; Sudman, M; Marion, MC; Langefeld, CD; Becker, ML; Thompson, SD.
Acr Open Rheumatology.
2019;
1:58-62.
Influence of CYP2C19 Metabolizer Status on Escitalopram/Citalopram Tolerability and Response in Youth With Anxiety and Depressive Disorders.
Aldrich, SL; Poweleit, EA; Prows, CA; Martin, LJ; Strawn, JR; Ramsey, LB.
Frontiers in Pharmacology.
2019;
10.
Implementation of Pharmacogenetics at Cincinnati Children's Hospital Medical Center: Lessons Learned Over 14 Years of Personalizing Medicine.
Ramsey, LB; Prows, CA; Zhang, K; Saldana, SN; Sorter, MT; Pestian, JP; Wenstrup, RJ; Vinks, AA; Glauser, TA.
Clinical Pharmacology and Therapeutics.
2019;
105:49-52.
Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance.
Ramsey, LB; Balis, FM; O'Brien, MM; Schmiegelow, K; Pauley, JL; Bleyer, A; Widemann, BC; Askenazi, D; Bergeron, S; Shirali, A; et al.
The Oncologist.
2018;
23:52-61.